Here are relevant reports on : gastrointestinal-cancer-therapeutics-market
-
Noninvasive Cancer Diagnostics Market by Instruments (Solid Tumor, Blood Cancer, Lung Cancer, Breast Cancer), Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics) - Analysis & Global Forecast to 2019
The global non-invasive cancer diagnostic market is expected to show considerable growth during the forecast period. This is attributed to growing cancer cases worldwide, especially breast and lung cancer. In 2013, in the U.S. there were more than 1,660,290 new cases of all type of cancers diagnosed in 2013 (American Cancer Society). Increased healthcare expenditure and increase research and development activities are some of the other factors driving the growth of this market. However factors such as high cost of treatment, and stringent regulatory guidelines are limiting the market growth.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
- Published: December 2013
- Price: $ 4950
- TOC Available:
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
RNAI Technology Market- by Application (Research, Therapeutics) - Global Forecasts to 2019
The report presents the latest advances in RNAi technologies and their clinical implication as a therapeutic platform. It charts the current trends in RNAi therapeutics, and analyzes the opportunities and challenges faced by the RNAi companies. The focus will be on the clinical needs, patented technologies and the competitive landscape across geographies.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals) & Region - Global Forecast to 2026
The global cancer diagnostics market growth is primed to transition from $17.2 billion in 2021 to $26.6 billion by 2026, showcasing a strong CAGR of 11.5%. This growth is driven by the increasing incidence of cancer and the rise in private diagnostic centers. Opportunities are enhanced by government and healthcare provider recommendations for early cancer screening.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
Gastrointestinal Stent Market by Product (Biliary Stents, Duodenal Stents, Colonic Stents, Pancreatic Stents and Esophageal Stents), Material (Self-Expanding Metal Stents and Plastic Stents), Application, End User & Region - Global Forecast to 2026
The size of global gastrointestinal stent market in terms of revenue was estimated to be worth $457 million in 2021 and is poised to reach $600 million by 2026, growing at a CAGR of 5.6% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: February 2022
- Price: $ 4950
- TOC Available:
-
Superdisintegrants Market by Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Formulation (Tablet, Capsules), Therapeutic Area (Gastrointestinal, Cardiovascular, Neurology, Oncology, Hematology) - Global Forecast to 2023
The global superdisintegrants market is projected to reach USD 536.5 million by 2023, growing at a CAGR of 7.9%. The prominent players in the global superdisintegrants market are Ashland Inc. (US), BASF SE (Germany), DowDuPont (US), JRS Pharma (Germany), DFE Pharma (Germany), Roquette Freres (France), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), and Avantor Performance Materials, LLC (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
-
Clinical Microbiology Market by Product (Instrument (Incubators), Analyzer (Microscope), Reagent, Kits, Media], Disease Area (Respiratory, Gastrointestinal, STD, UTI), End User (Hospitals, Diagnostic Center, Research Institutes) - Global Forecast to 2030
The global clinical microbiology market, valued at US$5.08 billion in 2024, stood at US$5.33 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2025 to 2030, culminating in a forecasted valuation of US$7.34 billion by the end of the period. A key factor contributing to market growth is the rising technological advancements that have enabled the development of advanced microbial identification methods and improved antibiotic susceptibility testing.
- Published: September 2025
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
